{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:42:45Z","timestamp":1787240565618,"version":"build-2736575974"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"\n Importance<\/jats:title>\n Oral tamoxifen citrate benefits women with ductal carcinoma in situ (DCIS), but concern about toxic effects has limited acceptance. Previous pilot studies have suggested transdermal 4-hydroxytamoxifen gel has equivalent antiproliferative efficacy to oral tamoxifen, with low systemic exposure.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To demonstrate that 4-hydroxytamoxifen gel applied to the breast skin is noninferior to oral tamoxifen in its antiproliferative effect in DCIS lesions.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This randomized, double-blind, phase 2 preoperative window trial was performed at multicenter breast surgery referral practices from May 31, 2017, to January 27, 2021. Among 408 women with estrogen receptor\u2013positive DCIS who were approached, 120 consented and 100 initiated study treatment. The most common reasons for nonparticipation were surgical delay, disinterest in research, and concerns about toxic effects. Data were analyzed from January 26, 2021, to October 5, 2022.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Random assignment to oral tamoxifen citrate, 20 mg\/d, and gel placebo or 4-hydroxytamoxifen gel, 2 mg\/d per breast, and oral placebo, for 4 to 10 weeks, followed by DCIS resection.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary end point was absolute change in DCIS Ki-67 labeling index (Ki67-LI). Secondary end points included 12-gene DCIS Score, breast tissue tamoxifen metabolite concentrations, tamoxifen-responsive plasma protein levels, and patient-reported symptoms. Noninferiority of Ki67-LI reduction by 4-hydroxytamoxifen gel was tested using analysis of covariance; within- and between-arm comparisons were performed with paired\n t<\/jats:italic>\n tests for mean values or the Wilcoxon rank sum test for medians.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 90 participants completing treatment (mean [SD] age, 55 [11] years; 8 [8.9%] Asian, 16 [17.8%] Black, 8 [8.9%] Latina, and 53 [58.9%] White), 15 lacked residual DCIS in the surgical sample, leaving 75 evaluable for the primary end point analysis (40 in the oral tamoxifen group and 35 in the 4-hydroxytamoxifen gel group). Posttreatment Ki67-LI was 3.3% higher (80% CI, 2.1%-4.6%) in the 4-hydroxytamoxifen gel group compared with the oral tamoxifen group, exceeding the noninferiority margin (2.6%). The DCIS Score decreased more with oral tamoxifen treatment (\u221216 [95% CI, \u221222 to \u22129.4]) than with 4-hydroxytamoxifen gel (\u22121.8 [95% CI, \u22125.8 to 2.3]). The median 4-hydroxytamoxifen concentrations deep in the breast were nonsignificantly higher in the oral tamoxifen group (5.7 [IQR, 4.0-7.9] vs 3.8 [IQR, 1.3-7.9] ng\/g), whereas endoxifen was abundant in the oral tamoxifen group and minimal in the 4-hydroxytamoxifen gel group (median, 13.0 [IQR, 8.9-20.6] vs 0.3 [IQR, 0-0.3] ng\/g;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Oral tamoxifen caused expected adverse changes in plasma protein levels and vasomotor symptoms, with minimal changes in the transdermal group.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, antiproliferative noninferiority of 4-hydroxytamoxifen gel to oral tamoxifen was not confirmed, potentially owing to endoxifen exposure differences. New transdermal approaches must deliver higher drug quantities and\/or include the most potent metabolites.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02993159<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamasurg.2023.5113","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T12:30:43Z","timestamp":1698064243000},"page":"1265","source":"Crossref","is-referenced-by-count":9,"title":["Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ"],"prefix":"10.1001","volume":"158","author":[{"given":"Seema A.","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Xu","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Luis Z.","family":"Blanco","sequence":"additional","affiliation":[{"name":"Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza M.","family":"Akasha","sequence":"additional","affiliation":[{"name":"Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pilewskie","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Degnim","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"AlHilli","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospitals, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Shelley","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Michael","family":"Guenther","sequence":"additional","affiliation":[{"name":"Deparmtent of Surgery, St Elizabeth Healthcare, Edgewood, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masha","family":"Kocherginsky","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Benante","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Helland","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Steinar","family":"Hustad","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demirkan B.","family":"Gursel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Mellgren","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Dimond","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, National Cancer Institute Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Perloff","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, National Cancer Institute Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy M.","family":"Heckman-Stoddard","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, National Cancer Institute Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oukseub","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"soi230075r1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10549-011-1430-5","article-title":"Characterizing the impact of 25 years of DCIS treatment.","volume":"129","author":"Ozanne","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"soi230075r2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast cancer mortality after a diagnosis of ductal carcinoma in situ.","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"soi230075r3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv263","article-title":"Trends in treatment patterns and outcomes for ductal carcinoma in situ.","volume":"107","author":"Worni","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"9169","key":"soi230075r4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.","volume":"353","author":"Fisher","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"soi230075r5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jnci\/djr027","article-title":"Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.","volume":"103","author":"Wapnir","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"soi230075r6","doi-asserted-by":"publisher","first-page":"m1570","DOI":"10.1136\/bmj.m1570","article-title":"Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study.","volume":"369","author":"Mannu","year":"2020","journal-title":"BMJ"},{"issue":"18","key":"soi230075r7","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"9336","key":"soi230075r8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"soi230075r9","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/cncr.v100:5","article-title":"Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.","volume":"100","author":"Yen","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"soi230075r10","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1002\/cncr.v103:10","article-title":"Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.","volume":"103","author":"Melnikow","year":"2005","journal-title":"Cancer"},{"issue":"7","key":"soi230075r11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","article-title":"Patient reluctance toward tamoxifen use for breast cancer primary prevention.","volume":"8","author":"Port","year":"2001","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"soi230075r12","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1002\/cncr.v100:9","article-title":"Acceptance of tamoxifen chemoprevention by physicians and women at risk.","volume":"100","author":"Tchou","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"soi230075r13","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","article-title":"Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.","volume":"17","author":"Day","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"soi230075r14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10549-018-4775-1","article-title":"Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.","volume":"170","author":"Hackett","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"25","key":"soi230075r15","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women.","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"issue":"9922","key":"soi230075r16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"soi230075r17","first-page":"1521","article-title":"trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast.","volume":"46","author":"Mauvais-Javis","year":"1986","journal-title":"Cancer Res"},{"issue":"3","key":"soi230075r18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1210\/endo.138.3.4979","article-title":"Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.","volume":"138","author":"Kuiper","year":"1997","journal-title":"Endocrinology"},{"issue":"6-7","key":"soi230075r19","first-page":"741","article-title":"Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites.","volume":"64","author":"Wakeling","year":"1980","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"soi230075r20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/B:BREA.0000025406.31193.e8","article-title":"Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.","volume":"85","author":"Johnson","year":"2004","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"soi230075r21","first-page":"112","article-title":"Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.","volume":"44","author":"Katzenellenbogen","year":"1984","journal-title":"Cancer Res"},{"issue":"24 Pt 1","key":"soi230075r22","first-page":"7193","article-title":"Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture.","volume":"48","author":"Malet","year":"1988","journal-title":"Cancer Res"},{"issue":"5","key":"soi230075r23","first-page":"737","article-title":"Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.","volume":"38","author":"Murphy","year":"1990","journal-title":"Mol Pharmacol"},{"issue":"5","key":"soi230075r24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00280-004-0926-7","article-title":"Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.","volume":"55","author":"Lim","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"soi230075r25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/BF00685799","article-title":"Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue.","volume":"36","author":"Pujol","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"soi230075r26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-007-9507-x","article-title":"A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women.","volume":"106","author":"Mansel","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"soi230075r27","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1200\/JCO.2005.06.064","article-title":"Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.","volume":"23","author":"Rouanet","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14","key":"soi230075r28","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1158\/1078-0432.CCR-13-3045","article-title":"A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.","volume":"20","author":"Lee","year":"2014","journal-title":"Clin Cancer Res"},{"key":"soi230075r29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/1471-2407-9-285","article-title":"Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.","volume":"9","author":"Chen","year":"2009","journal-title":"BMC Cancer"},{"issue":"12","key":"soi230075r30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1200\/JCO.19.00510","article-title":"Phase II single-arm study of preoperative letrozole for estrogen receptor-positive postmenopausal ductal carcinoma in situ: CALGB 40903 (Alliance).","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"soi230075r31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.bjc.6601013","article-title":"Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.","volume":"89","author":"Boland","year":"2003","journal-title":"Br J Cancer"},{"issue":"1","key":"soi230075r33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13063-018-3108-3","article-title":"The correlation between baseline score and post-intervention score, and its implications for statistical analysis.","volume":"20","author":"Clifton","year":"2019","journal-title":"Trials"},{"key":"soi230075r34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2288-1-6","article-title":"The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study.","volume":"1","author":"Vickers","year":"2001","journal-title":"BMC Med Res Methodol"},{"issue":"7321","key":"soi230075r35","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1136\/bmj.323.7321.1123","article-title":"Statistics notes: analysing controlled trials with baseline and follow up measurements.","volume":"323","author":"Vickers","year":"2001","journal-title":"BMJ"},{"issue":"10","key":"soi230075r36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.","volume":"105","author":"Solin","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"soi230075r37","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10549-007-9682-9","article-title":"Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women.","volume":"109","author":"Cella","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"soi230075r38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/jpm11030201","article-title":"Generating a precision endoxifen prediction algorithm to advance personalized tamoxifen treatment in patients with breast cancer.","volume":"11","author":"Helland","year":"2021","journal-title":"J Pers Med"},{"key":"soi230075r39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/BCTT","article-title":"In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast.","volume":"3","author":"Lee","year":"2011","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"6","key":"soi230075r40","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00280-015-2848-y","article-title":"Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.","volume":"76","author":"Lee","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"soi230075r42","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1245\/s10434-016-5268-2","article-title":"Do LORIS trial eligibility criteria identify a ductal carcinoma in situ patient population at low risk of upgrade to invasive carcinoma?","volume":"23","author":"Pilewskie","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"soi230075r43","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia.","volume":"37","author":"DeCensi","year":"2019","journal-title":"J Clin Oncol"},{"key":"soi230075r32","unstructured":"National Cancer Institute Division of Cancer Treatment & Diagnosis. Cancer therapy evaluation program. Updated April 19, 2021. Accessed January 22, 2023. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"soi230075r41","unstructured":"Phase I trial of endoxifen gel versus placebo in women undergoing breast surgery. ClinicalTrials.gov identifier: NCT03317405. Accessed January 28, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03317405"},{"key":"soi230075r44","unstructured":"Afimoxifene in reducing the risk of breast cancer in women with mammographically dense breast. ClinicalTrials.gov identifier: NCT03063619. Accessed January 28, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03063619"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2811162\/jamasurgery_khan_2023_oi_230075_1702400566.49985.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T11:01:32Z","timestamp":1702465292000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2811162"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2023.5113","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}